Eliezer M. Van Allen

Dr. Eliezer M. Van Allen is an Associate Professor of Medicine at Harvard Medical School and Chief of the Division of Population Sciences at the Dana-Farber Cancer Institute. He is also an Institute Member at the Broad Institute of MIT and Harvard and a Member Researcher at The Parker Institute for Cancer Immunotherapy. His work bridges clinical oncology and computational biology to advance precision cancer medicine.

Dr. Van Allen’s research focuses on computational oncology, single-cell transcriptomics, cancer genomics, and translational research, particularly in prostate, pancreatic, melanoma, and kidney cancers. He pioneered the field of clinical computational oncology, developing AI-driven tools to interpret cancer genomes and uncover resistance mechanisms to therapy. His lab actively explores tumor evolution, immunogenomics, and the role of inherited and environmental factors in cancer progression.

The recent publications from his lab reflect a strong trend in applying artificial intelligence, single-cell and spatial multiomics, and deep learning to dissect tumor-immune interactions, identify biomarkers, and improve clinical decision-making in oncology. His work spans from algorithm development to real-world clinical implementation.

• Featured in Newsweek on 6 Lessons for Harnessing Artificial Intelligence
• Wall Street Journal feature on the Metastatic Prostate Cancer Project
• New York Times feature highlighting his work on cancer immunotherapy and genomics

Dr. Van Allen mentors a large team of students, postdoctoral fellows, and researchers, with multiple successful PhD and Master’s thesis defenses. His lab is actively involved in patient-partnered research through initiatives like mpcproject.org. He leads a dynamic research group focused on creating the next generation of computational oncologists and advancing the clinical interpretation of cancer genomes.

His lab, the Van Allen Lab, is dedicated to driving precision cancer medicine through innovative computational approaches. The team includes computational biologists, postdoctoral fellows, and clinical researchers working at the intersection of AI and oncology. The lab frequently welcomes new members and emphasizes collaborative, interdisciplinary science.